Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), is responsible for predominance of side-effects of Prempro and injuries being pursued in Prempro litigation. Menopausal and postmenopausal women have been repeatedly and erroneously over prescribed by their physicians indicating that Prempro should be taken indefinitely. Inappropriate Prempro labeling that failed to fully describe side-effects of Prempro and long-term dosage has created many serious and life threatening health risks for women. It is responsibility of drug manufacturer to protect women from harmful Prempro injury and to warn of side effects of Prempro.

Prempro litigation began after an article published in Journal of American Medical Association (AMA) revealed that side-effects of Wyeth's Prempro included increased risk of probable dementia in postmenopausal women 65 years or older.

The Women's Health Initiative (WHI) Memory Study enrolled 4,532 postmenopausal women free of probable dementia aged 65 years or older. Participants received either one daily Prempro tablet or a matching placebo in a randomized, double-blind, placebo-controlled clinical trial.

Because of life threatening Prempro side effects, Prempro class actions suits have been filed and Food and Drug Administration (FDA) and Wyeth have revised prescribing information to include a boxed warning stating that estrogens and estrogens plus progestin should not be used for prevention of heart disease.

The Prempro class action allegations rely on fact that boxed warning now includes risk information from Women's Health Initiative (WHI) study about increased risks of Prempro side effects of heart attacks, stroke, invasive breast cancer, pulmonary embolism (blood clots), and deep vein thrombosis in postmenopausal women. Estrogens with or without progestin should be prescribed at lowest effective doses and for shortest duration.